| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2036406 | Cell | 2010 | 5 Pages |
Abstract
To stem the spiraling cost of cancer treatment, a concerted effort is urgently needed to develop molecular diagnostics to better identify the patients that respond to expensive targeted therapies. Opportunities and obstacles in the development of such drug response biomarkers are discussed here.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
René Bernards,